Status and phase
Conditions
Treatments
About
The purpose of this study is to test the safety of a new type of IG-IMRT called "ultra-hypofractionated IG-IMRT" where a higher dose of radiation is given to the tumor during each treatment day. Since higher doses of radiation are used each day, the total number of treatment days needed to complete this type of radiation is only five instead of the 45-48 treatments currently used. Treatment takes place every other day and is complete after 2 weeks. If the patient decides to get this treatment, they will come in for 5 treatments. This is different from the 48 treatments they would get normally.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Eligibility is not restricted to MSKCC to confirm biopsy/diagnosis. Participating institution testing is sufficient.
Low and intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines.
Low risk patients will be defined as:
Intermediate risk patients will be defined as:
Additionally, patients will be required to meet the following criteria:
Exclusion criteria
Prior androgen deprivation therapy for prostate cancer
Elective pelvic lymph node irradiation
KPS < 70
Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease
Presence of distant metastasis as determined by:
o alkaline phosphatase > or = to ULN or
whole body bone scan positive for osseous metastases
Prior history of transurethral resection of the prostate
Prior history of chronic prostatitis
Prior history of urethral stricture
Prior history of pelvic irradiation
History of inflammatory bowel disease
Unable to give informed consent
Unable to complete quality of life questionnaires Abnormal complete blood count. Any of the following
Abnormal renal function tests (creatinine > 1.5)
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal